FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>LANE ANDREW H</u>						2. Issuer Name and Ticker or Trading Symbol ABBOTT LABORATORIES [ABT]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below)						
(Last) 100 ABE	OTT PAR	First) K ROAD	(Middle)				3. Date of Earliest Transaction (Month/Day/Year) 08/27/2021								below) EXECUTIVE VI		below)			
(Street) ABBOTT PARK IL 60064 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)								i. Indiv ine) X	,					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Date				2. Transa Date (Month/D	ay/Year) if a		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)				acquired (A) or D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common shares without par value 08/27/2					/2021	21			M		135,925	A	\$38.	.4	222,012(1)			D		
Common shares without par value 08/				08/27	/2021	.021					135,925	D	\$125.4	475 ⁽²⁾ 8		36,087		D		
Common shares without par value														1,543 ⁽³⁾			I	Profit Sharing Trust		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deer Execution if any (Month/E		4. Transa Code (8)				Expira	e Exer ation D h/Day/		7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		S	. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported Transacti	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amoun or Numbe of Shar	r		(Instr. 4)	(0)			
Option (right to buy) ⁽⁴⁾	\$38.4	08/27/2021			M	М		135,925	02/19	/2019	02/18/2026	Common Shares	135,9	25	\$0	0		D		

Explanation of Responses:

- 1. Includes shares acquired pursuant to a dividend reinvestment feature.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$124.96 to \$125.72, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- 3. Balance in the Abbott Laboratories Stock Retirement Trust as of August 27, 2021.
- 4. Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

Remarks:

These transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).

/s/ Andrew H. Lane by Jessica

08/31/2021 H. Paik, Attorney-in-Fact,

Attorney-in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.